Sovargen focuses on the research and the development of innovative new drugs based on precision medicine in the field of neurological diseases with high medical unmet needs.
Sovargen's science originated from discovering how somatic mutations arising from neural stem cells during development or over aging cause intractable brain disorders like epilepsy, brain tumor, Alzheimer's, and others.
Sovargen is doing the best it can to develop the treatments for rare neurological diseases whose progress has faced numerous challenges via the research and development of RNA therapeutics such as anti-sense oligo, siRNA, and mRNA.
Sovargen's science originated from discovering how somatic mutations arising from neural stem cells during development or over aging cause intractable brain disorders like epilepsy, brain tumor, Alzheimer's, and others.
Sovargen is doing the best it can to develop the treatments for rare neurological diseases whose progress has faced numerous challenges via the research and development of RNA therapeutics such as anti-sense oligo, siRNA, and mRNA.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
2018
Main Therapeutic Focus:
Lead Product in Development:
SVG102 (Intractable Epilepsy)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
